|
|
|
|
Rituximab therapy appears to be an effective option in patients with refractory AChR+MG, who were observed to have a durable response after treatment. Identification of markers of disease relapse and sustained remission are critical next steps in the development of pathophysiology-relevant, evidence-based practice parameters for rituximab in the treatment of MG. |
|